The first session, devoted to kinetics, consisted of information from studies involving 225 patients. In this session, we heard about the kinetics of cefuroxime in normal volunteers as well as some interesting data about the penetration of this drug into interstitial tissue fluid, cerebrospinal fluid, bronchial secretions, bile and bone.
The pharmacology in normal human volunteers *was presented by Dr Nakagawa from Japan. He confirmed information given in the earlier Introductory Session regarding the serum levels produced by several different doses given by either intravenous or intramuscular injection. These studies confirmed that mean peak levels were 23 ,ug/ml after i.v. injection of 1.0 g and 99 ,tg/ml following an i.m. injection of 1.5 g doses. Large amounts of cefuroxime were excreted in the urine. Using mathematically derived equations, Professor Brogard from Strasbourg calculated the elimination, distribution and absorption constants for cefuroxime, and confirmed its half-life of 60 minutes in man. He further calculated and confirmed the distribution volume after a 500 mg i.v. or i.m. dose. His data suggested that after a 500 mg i.v. dose given every 2 to 4 hours, the mean serum levels achieved in the average sized adult would consistently be several times greater than the MIC of sensitive organisms.
Interstitial tissue penetration studies were presented by Professor Simon from Kiel. Using a skin blister model, he was able to do steady-state infusion studies with cefuroxime which revealed a rapid penetration into this blister fluid. After a 6 hour period of observation, he noted that the serum and the interstitial fluid levels were very similar.
Pharmacokinetics of cefuroxime in bronchial secretions were studied by Professor Bergogne-Berezin from Paris. After a 750 mg dose, she observed that secretions obtained by tracheal suction or bronchoscopy contained levels of cefuroxime which were from 2 to 5 ,g/ml. These levels were higher than those achieved with several other cephalosporins. This level of cefuroxime was several times higher than the concentration needed to kill the Gram-positive bacterial flora responsible for most pulmonary infections.
Dr Norrby from Gothenburg presented data which suggested that the cerebrospinal fluid levels achieved after fairly large doses of cefuroxime were adequate to treat those pathogens commonly encountered in bacterial meningitis. In his paper he presented 2 cases of meningitis, one caused by Klebsiella and the other by Streptococcus pneumonice. Both patients had received 3 g of cefuroxime every 8 hours and both had levels of cefuroxime in the spinal fluid which were several times greater than the MICs of the organisms responsible for the meningitis. He further presented information using intraventricular injection of 50 mg in children, which suggested that the levels achieved were high and that this CSF transport phenomenon might be due to a passive rather than an active transport mechanism, as the levels persisted long after injection.
The significance of bile levels was thoroughly discussed during this session. In general, it was agreed that cefuroxime is excreted in large amounts in the bile, many times the MIC of most organisms usually encountered there. The obstructed bile duct has much lower and much poorer secretion levels than the non-obstructed. The data from this session further suggested that chronic inflammation of the gall bladder may lead to lower cefuroxime levels than those found in patients with acute gall bladder disease.
Dr Kosmidis from Athens further confirmed that patients with chronic bronchitis who had received at least 24 hours of cefuroxime therapy had levels of cefuroxime in their sputum which were generally more than sufficient to kill the usual pathogens encountered there. Dr Kosmidis also presented 2 patients in whom he had studied bone levels. These patients did not have bone infection and the bone levels were done on bone taken at surgery after 24 hours of cefuroxime therapy. Levels achieved in this bone using 2 different assays were many times that needed for the usual pathogens in osteomyelitis.
In the 220 patients studied in this series the clinical effectiveness was impressive, there were very few cefuroxime failures although there were some super-infections, and Pseuidomonas species were the most commonly encountered.
The side effects were surprisingly few, and were mostly elevation of transaminase levels. The fact that transaminase elevations occurred in many patients who had underlying diseases would suggest that this may not be a drug-related phenomenon. A positive Coombs' test was encountered in several of the patients studied in the clinical trials as well as in one volunteer. Eosinophilia and skin rash were also encountered.
Professor M H Richmond (Department ofBacteriology, University ofBristol, UK) I am going to try and produce an overview of the microbiology session. The first part was concerned with trying to assess the in vitro activity of cefuroxime against organisms encountered in the clinical context. This was done quite comprehensively by a number of the speakers. It is clear that there is no worth while anti-Pseudononas activity. The compound is active against strains of Bacteroides if they do not make lactamase, but it is also accepted that if they do make lactamase (and a significant proportion of strains do) then cefuroxime is not likely to be effective.
The antibiotic is relatively active against strains of Proteus, Citrobacter, Acinetobacter and Serratia, though it was clear from some of the discussion that rather careful consideration of Proteus is required; some may be much more sensitive than others, but from Professor Goto's work, for example, the mean MICs against some Proteus species were in the order of 25-30 ,ug/ml. Passing on from Proteus to Escherichia coli and similar organisms, I was very impressed by the very high levels of effectiveness against these organisms when a selection was examined against cefuroxime. To introduce a comparative note, it was clear that cefuroxime was very much better than cephalothin, not so much in the absolute MIC values obtained but in the proportion of strains which were sensitive. That is an important point.
Two very important features of cefuroxime were seen in relation to Hamophilus influenza, and to Neisseria gonorrhaa. In each case the antibiotic clearly is very effective and very good MICs were obtained. I am sure that these are important points for the future. On the question of synergy, it was clear from some of the work presentednotably by Dr Sabaththat there was detectable synergy with some of the aminoglycosides and certainly no evidence to the contrary. Combination of cefuroxime with some of the more modem aminoglycosides looked as though it might be a useful approach.
There was then some discussion of ,B-lactamases, because one of the objects of developing cefuroxime was to produce an antibiotic which was effective against g-lactamase producing organisms.
Professor Sabath dealt with Staphylococcus and Gram positive organisms. I dealt with the Gram negatives. The summary is clear: cefuroxime is resistant, for practical purposes, to all the ,B-lactamases of these groups, with the proviso that it is hydrolyzed by the g-lactamase from
Bacteroides. Undoubtedly, the fact that cefuroxime is generally resistant to g-lactamases accounts for its activity against such a high proportion of E. coli isolates.
Finally, I would single out the paper by Dr Scott, concerned with more clinical work than the pre-clinical investigations that had gone before. He addressed himself to 3 questions: does cefuroxime work; does it achieve good serum levels and is it free of side effects? He was the first person in the meeting to give us the view (which has certainly been substantiated from elsewhere) that in very many interesting cases it does work and that it does achieve good serum levels. Although his results differed somewhat from the Glaxo data, in principle it did achieve good serum levels. As for the side-effects, cefuroxime seemed to be singularly free of them.
DISCUSSION
Dr R Norrby (Gothenburg) said that during an inflammatory reaction, cefuroxime could be expected to pass through the meninges to give high concentrations, as was the case with other gl-lactam antibiotics. However, he did not expect the same movement across intact meninges, and although much information was still lacking, did not expect the maximum concentration of a gl-lactam antibiotic in the CSF to exceed 10% of the peak concentration in serum.
Dr L 0 Gentry (Houston) said that one patient presented in a previous session with non-inflamed meninges had shown no detectable level of cefuroxime in spinal fluid even though he had received high drug doses.
Dr E S Snell (Greenford) said that preliminary investigation on placental transfer suggested that cefuroxime appeared in the umbilical cord blood to about the same extent as cephaloridine.
Dr G Sterner (Danderyd Hospital, Sweden)
The papers presented during the next session mostly concerned adults with lower respiratory tract infections, urinary tract infections, soft tissue infections and septicxamia. Professor de Sandre and his co-workers from Verona also presented some data from a small series on the prophylactic use of cefuroxime in cardiovascular, thoracic and abdominal surgery.
In this connection I asked if anybody else at the meeting had experience of the prophylactic use of cefuroxime, but I got no answer. At Danderyd Hospital we have given cefuroxime prophylactically to patients undergoing hip joint surgery in about 10 cases. Dr Dornbusch, using a new method, has shown that cefuroxime has a high affinity for bone.
The primary beneficial effect of an antibiotic drug is easy to demonstrate in urinary tract infection. However, the inclusion of pneumonia cases in a study for demonstrating the effect of a new antibiotic requires caution in drawing conclusions.
Positive blood cultures, bacteria isolated from pleural effusion or lung biopsy, from specimens obtained by transtracheal aspiration or by the bronchoscope establish a bacterial atiology in pneumonia cases. Such an atiology may also be established by demonstrating titre rises of antibodies against bacterial antigens. Such methods, however, are seldom used. I am not fully convinced that all cases of pneumonia presented during this meeting as successfully treated by cefuroxime were in fact caused by bacteria. I made this statement during the discussion of Professor Miki's paper, because he reported that only 74% of pneumonia in his material was cured by cefuroxime. Dr Levi from Brazil said that the aetiology of pneumonia in children with malnutrition in his country was almost entirely bacterial and he had successfully used cefuroxime in such a group of children. Even allowing for differences in living standards, I could not believe that 100% of pneumonia in children in Brazil was caused by bacteria. In my opinion we have to establish a bacterial atiology in pneumonia cases more carefully before we present the results of antibiotic treatment. Even before we had antibiotics, patients recovered from pneumonia.
However, we do know from many careful studies of the atiology of primary pneumonia in previously healthy individuals that if bacteria are involved Pneumococci still dominate, followed by Ha?mophilus influenza, and, thirdly, by Staphylococcus aureus. During influenza periods Staphylococcus aureus infections causing secondary
Frankfurt-on-Main, West Germany)
The main subject in this session was respiratory infection. The first 4 papers by Drs Gomme, Gobernado, Pettersson and Professor Babolini concerned a quite homogeneous group of patients. In total, 84 respiratory infections were treated and the clinical results overall were quite good.
The successful treatment of infections with Haemophih:s influenza, is unique and cannot be achieved with traditional cephalosporins. On the other hand, it is true to say that the real value of an antibiotic cannot be shown by clinical studies of this non-comparative type. The conclusions of such studies can only be that the antibiotic is effective. The real activity of cefuroxime has to be shown in the future, in infections where other cephalosporins, like cephalothin for example, have failed. I have no doubt that cefuroxime will be an important antibiotic in the treatment of severe respiratory infections in the failure.
The last paper, by Mr Sales and Dr Rimmer showed in 19 patients that biliary infections can be treated with cefuroxime. The basic parameters of cefuroxime fulfil the requirements for the treatment of biliary infections and cefuroxime will be one of the alternatives to treat them.
Aspects of the dosage were interesting. The patients in the different studies received quite different dosages, starting at 750 mg daily. Most received 750 mg three times daily, but some received 3 times 1 g and the highest recorded dosage was 6 times 1 g. In my opinion, a three times daily dosage of 750 mg is quite low in patients with severe respiratory infections. In the future I would guess that for clinical work (at least in Germany) higher doses than 750 mg three times daily will be used.
Practical treatment with cefuroxime in the future will be done to a large extent in combinations. Probably 30-50% of patients will receive cifuroxime together with an aminoglycoside antibiotic. I missed clinical work on combinations of this type in this meeting but no doubt they will be done in the future. There also exists the possibility of making a combination ofcefuroxime with penicillins like azlocillin. Such a combination seems to be feasible. It closes the Pseudomonas gap in the cefuroxime spectrum and such combinations open a new possibility for real broad spectrum chemotherapy. But before the clinical use of such combinations, their possible interaction should be known. pneumonia are more common than during periods free from influenza virus infection. In secondary pneumonia, quite different bacterial strains dominate, namely, Gram-negative organisms. Cefuroxime, which attacks most of the previously mentioned bacteria, except Pseudomonas, seems to be a good alternative drug in the treatment of pneumonia in hospital patients, especially when they are critically ill and an antibiotic must be given at once, although the doctor may have no idea what type of bacteria cause the infection. The same may be true in cases of septicwmia during the first day of hospitalization. The results presented in this session showed good evidence for giving such advice.
The data presented also showed that in a few cases a slight rise of transaminase and alkaline phosphatase occurred, but the values were normalized after treatment was discontinued.
A final favourable feature of the use of this new drug is that the i.m. route gives high serum concentrations, and the injections are mostly painless, except apparently in the cases reported from Osaka.
DISCUSSION
Dr R Norrby (Gothenburg) said that some believed that a drug which was useful or even vital in serious infection should never be used prophylactically. He felt this view was extreme, but one should be very careful in using cefuroxime, a valuable drug in the treatment of serious infections, for prophylactic use, especially in orthopsedic surgery. It might, however, be useful for abdominal surgery.
Dr H Gaya (London) agreed. He felt that no valuable therapeutic agents should be used either prophylactically or topically. Centres which had used gentamicin topically had problems of resistance related directly to the extent of its topical use. Centres which had given it prophylactically, particularly leukwmia units, had also found serious problems of gentamicin resistance and there was no reason to believe that the situation was different with any other antibiotic. Agents such as cefuroxime should simply not be used for prophylaxis.
Dr Sterner also agreed that the drug should not be used prophylactically. The study by Dr Dornbusch which he had mentioned had been carried out to establish whether the drug had affinity for bone. Dr Price (Chairman) said that at the time an attempt was being made to prevent an osteomyelitis which was considered imminent. Dr A I M Cook (Liverpool) as a surgeon, frequently used prophylactic antibiotics, and his patients seemed to do better. In biliary disease with an obstructed bile duct, workers in Birmingham had shown that antibiotics given at the time of surgery were beneficial. Many vascular surgeons were reluctant to place an aortic graft unless the patient had received antibiotics.
Dr R Norrby (Gothenburg) said that there were instances in which cefuroxime should be used prophylactically as in biliary surgery. But to use a drug which one might need to treat a clinical infection was often not considered good policy.
Professor W Brumfitt (London) questioned the evidence for the value of prophylaxis. One investigation had compared unconscious patients with respiratory problems, one group on prophylaxis, the other group not. Those on prophylaxis did less well, because the others were colonized by sensitive organisms which could be promptly treated. As to bile infection, antibiotics were being used to treat an infection that was already present in order to stop it spreading and causing wound infection. The term prophylaxis, in this context, was inappropriate.
Professor H C Neu (New York) thought that in cardiac surgery it might be wise to use the most effective agent for several days. Most infections in these patients were sternal wound infections that might progress to serious infection of the prosthetic valve. Dr A Percival (Liverpool) said that much prophylactic treatment was carried on for too long. Studies in Bristol and London had shown considerable success with prophylaxis limited to 1 or 2 doses. It seemed less likely that such doses would lead to the emergence of resistant organisms.
Professor W Brumfitt (London) said that one leading British hip replacement surgeon used no prophylaxis and had no sepsis. The skills of the surgeon had to be taken into account.
Dr Price (Chairman) referred to a paper on surgery for the Middlesex Hospital which reported that postoperative wound infection varied with the expertise of the operator. Distinction between prophylaxis and prevention was left to the individual doctor, but he endorsed the need to avoid inducing resistant organisms.
Treponema pallidum and, therefore, to have that preferential potential over spectinomycin.
Another feature of the ,B-lactamase producing strains has been their relative insusceptibility to tetracyclines. Minimum Inhibitory Concentrations have been of the order of 1, 2 or even 4 ,ug/ml. It has been shown that even such small diminution in susceptibility is definitely associated with reduced success rates when giving a tetracycline 500 mg orally even for 7 days. There is a 30-40% failure rate, which imposes a limitation on the use of tetracyclines.
Some are now wondering whether the venereologist should start treating the patients and not just the gonococci. In that context cefuroxime is surprisingly disappointing in its effect in vitro against Chlamydia, in that it is relatively inactive.
As to the future, what happens to gonococci will depend on 2 factors, first their ability to acquire greater degrees of inherent non ,Blactamase mediated resistance, and, secondly, the possibility that some gonococci could acquire another ,B-lactamase which was active against cephalosporins. However, most of those enzymes are chromosomally mediated so that does not seem to be very likely at the moment.
Professor W Brumfitt (Royal Free Hospital, London, UK)
We heard excellent papers during the session devoted to the treatment of infections of the urinary tract. Infections were either due to resistant bacteria or the patients had abnormalities of the renal tract or they were compromised hosts. I was very impressed at the serotyping efforts to decide whether the infection had been eradicated or whether it had returned without eradication, which I think is very important. Dr Boewering diagnosed his by suprapubic puncture. Dr Gomez-Lus gave us a very interesting paper and then Professor Naide reported a series of patients taken from 10 departments of urology and gynecology. The question to be asked is whether the bacterial ecology is the same in all of these cases. However, there is no doubt at all that the administration of this drug is safe, and although it is slightly painful it is not intolerably so.
Data were presented on elderly patients where infections are known to recur over and over again. In my view, if the original organism is eradicated, that is a success. If there is a reinfection, that is another episode.
The question was discussed of giving aminoglycosides with cefuroxime. I would urge workers not to do so. We have very large experience at the Dr A Percival (University ofLiverpool, UK) I have a relatively easy task, because the session of which I was chairman considered infection caused by only one organism. But we ought to recognize that it is a very common infection. Indeed, gonorrhcea is said to be the commonest communicable bacterial infection in the community. It is commoner in some areas than others, and it is increasing everywhere, particularly in Africa where it is a major social problem.
Previously gonococci were less sensitive to cephalosporins than they were to benzylpenicillin. Clinical results using these earlier cephalosporins were not very satisfactory but in this session we heard results of both in vitro assessments of the sensitivity of gonococci to cefuroxime and the results of treatment with it.
As to sensitivities, it is quite evident that cefuroxime is the most active of all the cephalosporins currently available against gonococci. It is at least 5-10 times more active than the other cephalosporins which are stable to the gonococcal /3-lactamase, and in particular cefuroxime shares with ampicillin the characteristic of being more active than benzylpenicillin against relatively insusceptible strains. Since it is stable and not inactivated by the gonococcal /3-lactamase, then the sensitivity of those strains is the same as for organisms that do not produce /-lactamase.
The treatment of 700-800 patients was described. Some centres had a 95 % cure rate using I g of cefuroxime in a single i.m. injection without probenecid. Some other centres use 1.5 g with or without probenecid. It seems to me that 1 g without probenecid will probably be adequate in those areas that do not have a high proportion of benzyl-penicillin insusceptible strains. But in places like the Far East, it might be as well to combine the 1 g with probenecid.
Such treatment has been effective in eradicating the gonococci, except perhaps from the throat, and there is not enough evidence available yet to establish whether they will be removed from there. We await further studies from Sweden. It is likely, from previous studies with other antibiotics that it will not be as good at removing gonococci from the throat as it is in removing them from the cervix and the rectum.
Of the alternative regimens to cefuroxime for gonococcal infection, particularly in an area where /3-lactamase producing strains are to be expected, spectinomycin works very well. However, that particular agent does not abort incubating syphilis either in the experimental animal or in humans. With cefuroxime we do not know yet, but it is likely to be effective against Royal Free Hospital in London. Of 1000 patients treated with aminoglycosides, 10% had VIII cranial nerve damage when tested. The session showed that cefuroxime is a valuable advance in treatment, but now we have to look in defined groups of patients to see the place of this antibiotic, for example in dysuria, frequency, bacteriuria in pregnancy and acute pyelonephritis. We also have to ask whether the patients are immunosuppressed or whether they have other abnormalities. All this must be done and proper comparative data must be established against another antibiotic which has similar indications 'and which at the present time is the best available.
It was interesting to see that success was achieved in treating prostatitis which, of course, is a very serious problem. If cefuroxime will deal with that, it could be a most important development.
There was considerable variation in dosage and we shall have to consider the current dosage and duration. These are very important matters. I would hope that these trials would be done in hospitals where the bacterial ecology is known, otherwise cross-infecting organisms resistant to cefuroxime might appear.
To conclude then, we must also look into the natural history. When we treat patients we should divide them into the dysuria frequency syndrome, asymptomatic bacteriuria, acute and chronic pyelonephritis. We must ask whether they have had a transplantation or whether they have just a simple pyelonephritis of pregnancy, which in my experience resolves very well. The next step is obvious. We have to localize the infection, remembering the existence of asymptomatic pyelonephritis. We have to distinguish between recurrent infections and we also have to look into the relapses. Then, because an injection has to be given, I think that it will be necessary to ask whether this drug is suitable for out-patients in the long term or whether, because it appears to be so good, we should start off with it in hospital for 1-2 days and then go on to oral therapy, perhaps with cephalexin.
These are some of the problems that we must now address ourselves to in strictly similar groups of patients. Only in that way will the place of cefuroxime be finally decided, but I think it has very good possibilities.
Professor H C Neu (Columbia University, New York, USA)
The session which dealt with the use ofcefuroxime in renal insufficiency attacked several interesting and very important topics. We started with a paper by Dr Sack and his colleagues from Luibeck, in which they looked at 2 crucial problems for patients who had renal insufficiency.
Firstly they looked at the question of whether or not the compound was useful in a chronic model of Escherichia coli pyelonephritis. They compared the activity of cefuroxime with cephalothin, cephaloridine, cephacetrile and cefazolin. Except in one instance, in which it was comparable to cefazolin, the drug clearly was the best compound in this particular pyelonephritis model. They then progressed to the question of toxicity which we had also heard discussed at the introductory session of this interesting meeting. They gave large doses of cefuroxime to albino Wistar rats and it requiied up to 5000 mg/kg/day to cause abnormalities of urinary enzyme excretion. This could be contrasted with 500 mg/ kg/day for cephaloridine. Thus they clearly indicated that the drug was efficacious and of low toxicity.
Dr Kosmidis, from Professor Daidos' group in Athens, presented a very useful paper on the treatment of patients who had renal insufficiency and had both urinary and respiratory infections.
The most common organisms were Escherichia coli and indole positive Proteus. Interestingly, 25 of the 36 isolates were resistant to cephalothin and 16 were resistant to gentamicin. Clearly the patients had been selected for treatment with a drug of this type. All but one patient was improved or cured at the 2-week follow-up. I think this would meet Professor Brumfitt's criteria and it is particularly important in considering the indole positive Proteus infections.
Their study also showed that even with creatinine clearances below 10 ml/niin, cefuroxime yielded adequate urine levels in the range up to 100 ,g/ml and thus would be efficacious in this type of situation. The half-life of cefuroxime in patients with creatinine clearances below 10 was some 15 h and in anuric patients it ran to 24 h. They also did studies with hemodialysis, and there the half-life was reduced to 3.5 h with an extraction ratio of 0.18. They had only one patient with peritoneal dialysis and the half-life in that patient was 13 h. This was contrasted by a later presentation by Dr Gower, reporting a half-life of about 5.5 h. Thus in the area of peritoneal dialysis, more work will be necessary.
The group summarized their recommendations for use of the drug. Down to a creatinine clearance of 30 ml, minimal reduction in dosage was needed. Below that, they felt that 1 g/1.73 m2 every 24 h would probably produce adequate serum and urine levels.
The subsequent paper by Professor Hoeffier from Darmstadt showed that the clearance of cefuroxime was equivalent to that of 51Cr-EDTA and that there was an apparent volume of Pettay reported so-called therapeutic blood levels of cefuroxime after giving 10 mg/kg/day of cefuroxime in the smallest prematurely-born babies and 30 mg/kg/day to full-term infants. On the other hand, doses as high as 100 mg/kg/day had been judged as safe at least on the basis of short-term follow-up by some others. We do not know what the optimal dose is, but probably it is somewhere between these extreme levels. The level of cefuroxime recorded in CSF was about 20 % of that recorded in the serum. We all agreed that in treating meningitis, the dose should be high, at least 50-100 mg/kg/day. In all the studies from West Germany, France, Italy and Finland, the clinical efficacy of cefuroxime was equally satisfactory. However, 2 reinfections of the urinary tract by sensitive Escherichia coli were reported by Nyman from Lahti and some single failures in staphylococcal disease and meningitis were observed. Occasional rash, possible eosinophilia, elevation of liver enzymes, possible elevation of blood urine nitrogen and in one case possible fall of hemoglobin level, were the only side-effects reported in the session. No severe side effects were seen.
From theoretical considerations and on the basis of the studies in children reported at this meeting, one should consider cefuroxime to be a promising antibiotic in pediatrics. The studies encourage further clinical trials. The need for a comprehensive series of antibiotics is especially obvious in pediatrics. Infections are by far the most common disease group in children. I have calculated that the annual rate of feverish infections in the children of the world is at least 2 x 10' and it may be much higher. We pwdiatricians welcome all good new antibiotics, and we hope that cefuroxime will be a valuable poediatric drug.
DISCUSSION
Dr J Kosmidis (Athens) said that their group had studied the kinetics of peritoneal dialysis in 3 patients not one. The mean half-life values were 8.8, 14.5 and 17.5 h. All 3 patients were anuric.
Professor C S Goodwin (Perth) said that on the question of assaying cephalosporins in the urine, some days after treatment, they had shown that the /3-lactamase of Bacillus cereus will destroy cefuroxime and other cephalosporins but not cephamycins. The enzyme might therefore be used in an assay system. distribution of 21.3 % of the body weight. They were able to devise a programme giving lower dosage in patients with anuria, 375 mg/24 h. I think again there will have to be some adjustment as to what exactly is the proper dose in anuria. Dr Graninger, from Professor Spitzy's group in Vienna, dealt with the use of cefuroxime in patients with chronic pyelonephritis. Most of them had failed on previous chemotherapy and had underlying structural abnormalities. They had a favourable outcome in 9 of 15 patients. They attributed the failures primarily to major structural anomalies and not to development of resistant organisms. This group also had 6 patients with osteomyelitis that they treated with 2-6 g for up to 22 days. Five of the 6 patients had a favourable outcome.
Dr Gower from London had also determined the half-life of cefuroxime. It was encouraging that his results were similar to the Greek group with a half-life of 3.1 h on hmmodialysis. Their overall assessment was that cefuroxime could safely be used in patients with renal insufficiency; that it is effective in chronic pyelonephritis (even in some patients with major structural abnormalities) and that it is an alternative drug to the aminoglycosides in such patients because of its enlarged spectrum of activity against /B-lactamase producing organisms.
It is clear that we need some further studies of peritoneal dialysis and perhaps some further pharmacokinetic data. But I think because of the safety of the drug, there should not be excessive concern over precise blood levels. A dose of 375-1000 mg every 24 h for patients in anuria should be quite effective.
Professor K Kouvalainen (University Central Hospital, Oulu, Finland) In the studies reported in the pxdiatric session, cefuroxime had been given to 201 children. About half of the series consisted of newborn infants. There were cases with urinary tract infection, bacterial respiratory infection; and neonatal sepsis and other infections.
In the papers by Drs Renlund and Pettay from Helsinki, and Dr Wilkinson and his co-workers from Munich, it was significant that the half-life of cefuroxime in newborn infants is 3-5 or 4-6 times that observed in adults. We do not yet know when the half-life will be normalized, but theoretically this might take place in the course of the first 3-6 months. Some data deriving from Dr Sorin's work from Paris support such a view.
There was much discussion as to the optimal dosage for neonates and infants. Renlund and Dr H H Schassen (Hamburg) asked what was the highest recommended dose ofcefuroxime in severe infections such as Gram negative septicemia or endocarditis. The suggestion had been made of limiting cefuroxime to 6 g daily and his impression was that its bactericidal effect could be distinctly improved by combination with an aminoglycoside.
Professor Stille said that in the early days of an antibiotic it was wise to use it with caution. Total daily dosage of 6 g should not be exceeded. With Pseudomonas infection no effect could be obtained at much higher dosages.
Professor Neu said he knew of no data in neutrop,enic patients of a failure to respond to adequate therapy with either penicillin or cephalosporin. The same was not always true with aminoglycosides in neutropxnic patients. It might be necessary to make some upward adjustment of the dose to maintain serum levels above the MIC. However, he was not convinced that it was necessary to use it with aminoglycosides, except perhaps in a mixed infection with Pseudomonas. Dr Price (Chairman) said that it was now possible to put forward recommendations on dosage, based on these various clinical reports. They would be described before the end of the session but at present the evidence did not seem to call for any restriction in drug usage.
Professor G K Daikos (Athens) said that he had had a case of endocarditis caused by Streptococcus viridans. The case lasted for 6 weeks and the effect of 6 g daily of cefuroxime was very good before the patient died of an aortic aneurism.
Dr G Spelta (Verona) said that they had examined the effect of cephalosporins on Treponema pallidum. Cefuroxime was slightly less active than penicillin, but more active than other cephalosporins, showing activity at 1 ,ug/ml. Dr L 0 Gentry said that MIC values will vary from one location to another. In his hospital using commonly accepted disc criteria, 11% of Escherichia coli could be described as resistant, although the drug had not been used clinically there. However, although the MICs of some of these resistant strains were high, the others were just outside the range of inhibitory concentration and with a drug as safe as this he would be prepared to increase the daily dosage to eliminate an E. coli with a higher MIC than a sensitive strain.
Dr Price (Chairman) then asked Dr Norrby to sum up the Conference as a whole.
